Search company, investor...

Elpiscience Biopharmaceuticals

Founded Year



Series C | Alive

Total Raised


Last Raised

$105M | 2 yrs ago

About Elpiscience Biopharmaceuticals

Elpiscience Biopharmaceuticals is an immunology-driven company that develops immunotherapies to fight cancer.

Headquarters Location

987 Cailun Rd., Pudong 3F

Shanghai, Shanghai, 201203,


+86 21 50651310

Compete with Elpiscience Biopharmaceuticals?

Ensure that your company and products are accurately represented on our platform.

Elpiscience Biopharmaceuticals's Products & Differentiators


    ES002, a potentially best-in-class anti-CD39 antibody which binds to CD39 with sub-nanomolar binding affinity and is designed to block CD39 ATPase activity.

Expert Collections containing Elpiscience Biopharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Elpiscience Biopharmaceuticals is included in 3 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest Elpiscience Biopharmaceuticals News

Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of First-in-Class Anti-CD39xTGF-β Bispecific Antibody ES014

Feb 27, 2023

SHANGHAI & SUZHOU, China & GERMANTOWN, Md.--(BUSINESS WIRE)--Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide, today announced that the first patient has been dosed in a Phase 1 clinical trial of ES014, a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb). The principal investigator of the study is Professor Lu Shun, Director of Oncology Department

Elpiscience Biopharmaceuticals Frequently Asked Questions (FAQ)

  • When was Elpiscience Biopharmaceuticals founded?

    Elpiscience Biopharmaceuticals was founded in 2017.

  • Where is Elpiscience Biopharmaceuticals's headquarters?

    Elpiscience Biopharmaceuticals's headquarters is located at 987 Cailun Rd., Pudong, Shanghai.

  • What is Elpiscience Biopharmaceuticals's latest funding round?

    Elpiscience Biopharmaceuticals's latest funding round is Series C.

  • How much did Elpiscience Biopharmaceuticals raise?

    Elpiscience Biopharmaceuticals raised a total of $260M.

  • Who are the investors of Elpiscience Biopharmaceuticals?

    Investors of Elpiscience Biopharmaceuticals include Lilly Asia Ventures, Hillhouse Capital Management, CDH Investments, DYEE Capital, Oriza Holdings and 14 more.

  • What products does Elpiscience Biopharmaceuticals offer?

    Elpiscience Biopharmaceuticals's products include ES002 and 4 more.

  • Who are Elpiscience Biopharmaceuticals's customers?

    Customers of Elpiscience Biopharmaceuticals include and undefined.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.